Monitoring minimal residual disease by urinary or plasma circulating tumor DNA of KRAS mutation burden in colorectal cancer patients with resectable liver metastases
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F15%3A%230000215" target="_blank" >RIV/26475821:_____/15:#0000215 - isvavai.cz</a>
Result on the web
<a href="http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=3ce71c87-60c0-4dc9-ab79-97b2cbd78559&cKey=5186b725-e557-402c-bc1f-77fcbce36e41&mKey=" target="_blank" >http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=3ce71c87-60c0-4dc9-ab79-97b2cbd78559&cKey=5186b725-e557-402c-bc1f-77fcbce36e41&mKey=</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Monitoring minimal residual disease by urinary or plasma circulating tumor DNA of KRAS mutation burden in colorectal cancer patients with resectable liver metastases
Original language description
Poster describing quantitative changes of mutational KRAS burden in plasma and urinary ctDNA. Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the third leading cause of cancer deaths. Over half of patients with CRC will develop liver metastases. Surgical resection, in combination with systemic therapies, greatly improves long-term outcomes, and around 40% of patients with resected liver limited disease are alive 5 years after diagnosis. While tumor staging and radicality of surgery are commonly used for prognostic assessment, better non-invasive markers are needed for monitoring chemo-responsiveness, following minimal residual disease (MRD), and guiding complex treatment decisions in these patients. This study evaluated the utility of quantitating KRAS mutation burden in urinary and plasma ctDNA as a means of monitoring MRD in surgical CRC patients with liver limited metastases. We demonstrate for the first time that quantitative changes of mutational KRAS burde
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
EB - Genetics and molecular biology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/NT13660" target="_blank" >NT13660: Quality evaluation of multimodal treatment in patients with colorectal liver metastatic disease: Mutlicentric study within Czech complex oncology centres</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů